

Experiment Number: 97011-15
Test Type: 26-WEEK
Route: SKIN APPLICATION
Species/Strain: Mouse/FVB/N

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)

Test Compound: Transgenic model evaluation (Cyclophosphamide monohydrate)

CAS Number: 6055-19-2

Date Report Requested: 10/23/2014

Time Report Requested: 05:31:36

First Dose M/F: NA / NA

Lab: MBA

C Number:	C97011A
Lock Date:	09/18/2000
Cage Range:	All
Date Range:	All
Reasons For Removal:	All
Removal Date Range:	All
Treatment Groups:	All
Study Gender:	Both
PWG Approval Date	NONE

Experiment Number: 97011-15
Test Type: 26-WEEK
Route: SKIN APPLICATION
Species/Strain: Mouse/FVB/N

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)
Test Compound: Transgenic model evaluation (Cyclophosphamide monohydrate)
CAS Number: 6055-19-2

Date Report Requested: 10/23/2014
Time Report Requested: 05:31:36
First Dose M/F: NA / NA
Lab: MBA

FVB/N Mouse MALE	VEHICLE CONTROL	90 MG/KG
Disposition Summary		
Animals Initially In Study	15	15
Early Deaths		
Natural Death		1
Survivors		
Accidentally Killed	4	
Natural Death		1
Terminal Sacrifice	11	13
Animals Examined Microscopically	15	15
ALIMENTARY SYSTEM		
Liver	(15)	(15)
Hepatocyte, Necrosis, Focal	2 (13%)	
Salivary Glands	(15)	(15)
Inflammation, Chronic Active, Focal	1 (7%)	
Stomach, Forestomach	(15)	(14)
CARDIOVASCULAR SYSTEM		
None		
ENDOCRINE SYSTEM		
Adrenal Cortex	(15)	(14)
Subcapsular, Hyperplasia, Focal	1 (7%)	
Zona Glomer, Hyperplasia, Focal	1 (7%)	2 (14%)
Zona Glomer, Hypertrophy, Focal		1 (7%)
Zona Reticul, Vacuolization Cytoplasmic, Focal		1 (7%)
Adrenal Medulla	(15)	(14)
Pituitary Gland	(14)	(14)
Pars Distalis, Angiectasis, Focal	1 (7%)	
Pars Intermed, Hyperplasia, Focal		1 (7%)
Thyroid Gland	(14)	(14)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 97011-15

Test Type: 26-WEEK

Route: SKIN APPLICATION

Species/Strain: Mouse/FVB/N

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)

Test Compound: Transgenic model evaluation (Cyclophosphamide monohydrate)

CAS Number: 6055-19-2

Date Report Requested: 10/23/2014

Time Report Requested: 05:31:36

First Dose M/F: NA / NA

Lab: MBA

FVB/N Mouse MALE	VEHICLE CONTROL	90 MG/KG
GENERAL BODY SYSTEM		
None		
GENITAL SYSTEM		
Epididymis	(15)	(14)
Atrophy, Diffuse		1 (7%)
Granuloma Sperm, Focal	1 (7%)	
Hypospermia		11 (79%)
Inflammation, Acute, Diffuse		1 (7%)
Inflammation, Chronic Active, Diffuse		1 (7%)
Prostate	(0)	(1)
Inflammation, Acute, Focal		1 (100%)
Seminal Vesicle	(0)	(6)
Dilatation		5 (83%)
Inflammation, Chronic Active, Diffuse		1 (17%)
Inflammation, Chronic, Diffuse		1 (17%)
Testes	(15)	(15)
Germinal Epith, Degeneration		14 (93%)
Inflammation, Chronic Active, Diffuse		1 (7%)
HEMATOPOIETIC SYSTEM		
Bone Marrow	(15)	(14)
Myeloid Cell, Hyperplasia		2 (14%)
Lymph Node, Mandibular	(15)	(14)
Lymph Node, Mediastinal	(10)	(9)
Lymph Node, Mesenteric	(15)	(13)
Spleen	(15)	(14)
Hematopoietic Cell Proliferation	15 (100%)	14 (100%)
Lymph Follic, Depletion Cellular		1 (7%)
Thymus	(15)	(13)
Atrophy, Diffuse		4 (31%)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 97011-15

Test Type: 26-WEEK

Route: SKIN APPLICATION

Species/Strain: Mouse/FVB/N

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)

Test Compound: Transgenic model evaluation (Cyclophosphamide monohydrate)

CAS Number: 6055-19-2

Date Report Requested: 10/23/2014

Time Report Requested: 05:31:36

First Dose M/F: NA / NA

Lab: MBA

FVB/N Mouse MALE	VEHICLE CONTROL	90 MG/KG
INTEGUMENTARY SYSTEM		
Mammary Gland	(2)	(0)
Skin	(15)	(15)
Epidermis, SOA, Hyperplasia, Focal		2 (13%)
SOA, Hyperkeratosis, Focal		1 (7%)
MUSCULOSKELETAL SYSTEM		
None		
NERVOUS SYSTEM		
Peripheral Nerve	(15)	(15)
RESPIRATORY SYSTEM		
Lung	(15)	(15)
Alveolar Epith, Hyperplasia, Focal		5 (33%)
Alveolus, Hemorrhage, Focal	1 (7%)	
Alveolus, Inflammation, Chronic Active, Focal	1 (7%)	5 (33%)
Alveolus, Inflammation, Chronic, Focal		1 (7%)
Congestion, Diffuse		1 (7%)
Perivascular, Infiltration Cellular, Lymphocyte, Focal		3 (20%)
SPECIAL SENSES SYSTEM		
None		
URINARY SYSTEM		
Kidney	(15)	(14)
Inflammation, Chronic Active, Diffuse		1 (7%)
Medulla, Inflammation, Chronic Active, Focal		1 (7%)
Renal Tubule, Degeneration, Focal	1 (7%)	
Renal Tubule, Dilatation, Focal		1 (7%)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 97011-15

Test Type: 26-WEEK

Route: SKIN APPLICATION

Species/Strain: Mouse/FVB/N

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)

Test Compound: Transgenic model evaluation (Cyclophosphamide monohydrate)

CAS Number: 6055-19-2

Date Report Requested: 10/23/2014

Time Report Requested: 05:31:36

First Dose M/F: NA / NA

Lab: MBA

FVB/N Mouse MALE	VEHICLE CONTROL	90 MG/KG
Renal Tubule, Inflammation, Acute, Focal		1 (7%)
Urinary Bladder	(14)	(14)

END OF MALE DATA

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 97011-15
Test Type: 26-WEEK
Route: SKIN APPLICATION
Species/Strain: Mouse/FVB/N

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)
Test Compound: Transgenic model evaluation (Cyclophosphamide monohydrate)
CAS Number: 6055-19-2

Date Report Requested: 10/23/2014
Time Report Requested: 05:31:36
First Dose M/F: NA / NA
Lab: MBA

FVB/N Mouse FEMALE	VEHICLE CONTROL	90 MG/KG
Disposition Summary		
Animals Initially In Study	15	15
Early Deaths		
Accidentally Killed	1	
Moribund Sacrifice		1
Survivors		
Accidentally Killed	2	
Terminal Sacrifice	12	14
Animals Examined Microscopically	15	15
ALIMENTARY SYSTEM		
Liver	(15)	(15)
Hepatocyte, Necrosis, Focal	1 (7%)	
Infiltration Cellular, Lymphocyte, Focal	1 (7%)	
Salivary Glands	(15)	(15)
Infiltration Cellular, Lymphocyte, Focal	1 (7%)	
Stomach, Forestomach	(15)	(15)
Hyperkeratosis, Diffuse		1 (7%)
CARDIOVASCULAR SYSTEM		
None		
ENDOCRINE SYSTEM		
Adrenal Cortex	(15)	(15)
Subcapsular, Hyperplasia, Focal	4 (27%)	6 (40%)
Zona Reticul, Vacuolization Cytoplasmic, Diffuse	1 (7%)	3 (20%)
Zona Reticul, Vacuolization Cytoplasmic, Focal	14 (93%)	11 (73%)
Adrenal Medulla	(15)	(15)
Pituitary Gland	(13)	(12)
Thyroid Gland	(15)	(15)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 97011-15
Test Type: 26-WEEK
Route: SKIN APPLICATION
Species/Strain: Mouse/FVB/N

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)
Test Compound: Transgenic model evaluation (Cyclophosphamide monohydrate)
CAS Number: 6055-19-2

Date Report Requested: 10/23/2014
Time Report Requested: 05:31:36
First Dose M/F: NA / NA
Lab: MBA

FVB/N Mouse FEMALE	VEHICLE CONTROL	90 MG/KG
GENERAL BODY SYSTEM		
None		
GENITAL SYSTEM		
Ovary	(15)	(14)
Cyst	1 (7%)	1 (7%)
Degeneration, Focal	1 (7%)	
Uterus	(15)	(15)
Endometrium, Hyperplasia, Cystic	15 (100%)	15 (100%)
HEMATOPOIETIC SYSTEM		
Bone Marrow	(15)	(15)
Lymph Node	(1)	(0)
Lymph Node, Mandibular	(15)	(15)
Lymph Node, Mediastinal	(11)	(12)
Lymph Node, Mesenteric	(15)	(15)
Spleen	(15)	(15)
Hematopoietic Cell Proliferation	15 (100%)	14 (93%)
Lymph Follic, Depletion Cellular		1 (7%)
Pigmentation	8 (53%)	15 (100%)
Thymus	(15)	(14)
Atrophy, Diffuse		5 (36%)
Atrophy, Focal	2 (13%)	1 (7%)
INTEGUMENTARY SYSTEM		
Mammary Gland	(14)	(14)
Skin	(15)	(15)
MUSCULOSKELETAL SYSTEM		
None		
NERVOUS SYSTEM		

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 97011-15
Test Type: 26-WEEK
Route: SKIN APPLICATION
Species/Strain: Mouse/FVB/N

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)
Test Compound: Transgenic model evaluation (Cyclophosphamide monohydrate)
CAS Number: 6055-19-2

Date Report Requested: 10/23/2014
Time Report Requested: 05:31:36
First Dose M/F: NA / NA
Lab: MBA

FVB/N Mouse FEMALE	VEHICLE CONTROL	90 MG/KG
Brain	(1)	(0)
Peripheral Nerve	(15)	(15)
Spinal Cord	(1)	(0)
<hr/>		
RESPIRATORY SYSTEM		
Lung	(15)	(15)
Alveolar Epith, Hyperplasia, Focal		5 (33%)
Alveolus, Hemorrhage, Focal	1 (7%)	2 (13%)
Alveolus, Inflammation, Chronic Active, Focal	1 (7%)	
<hr/>		
SPECIAL SENSES SYSTEM		
None		
<hr/>		
URINARY SYSTEM		
Kidney	(15)	(15)
Inflammation, Acute, Focal		1 (7%)
Urinary Bladder	(15)	(15)

**** END OF REPORT ****